Georgia Hatzivassiliou

Scientist, Translational Oncology

POSTDOC MENTOR

"I have drawn inspiration from the creativity and drive that is an integral part of the research culture here."

• 5
  years at Genentech
• 5
  publications (2010-12)

I joined Genentech in 2008 as a Scientist in Translational Oncology after completing a postdoctoral fellowship at the University of Pennsylvania. What attracted me to Genentech was the potential to do cutting-edge research with a direct impact on cancer patients' lives.

Since joining, I have had the opportunity to work with colleagues across the organization on exciting projects and have drawn inspiration from the creativity and drive that is an integral part of the research culture here.

• My Focus

  My laboratory focuses on the validation of new therapeutic targets in oncology. A current area of interest is tumor metabolism. Alterations in metabolism are among the hallmarks of cancer and my lab is investigating the role of these alterations in cancer initiation and progression.

  We are also interested in oncogenic signaling pathways and the mechanisms by which they drive tumorigenesis.

• Publications

  • An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer

    Cancer Research, 2012, ISSN: 0008-5472

    McCleland, Mark L; Adler, Adam S; Shang, Yonglei; Hunsaker, Thomas; Truong, Tom; Peterson, David; Torres, Eric; Li, Li; Haley, Benjamin; Stephan, Jean-Philippe; Belvin, Marcia; Hatzivassiliou, Georgia; Blackwood, Elizabeth M; Corson, Laura; Evangelista, Marie; Zha, Jiping; Firestein, Ron

     View on PubMed

  • ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

    Molecular Cancer Therapeutics, 2012, ISSN: 1535-7163

    Hatzivassiliou, Georgia; Liu, Bonnie; O'Brien, Carol; Spoerke, Jill M; Hoeflich, Klaus P; Haverty, Peter M; Soriano, Robert; Forrest, William F; Heldens, Sherry; Chen, Huifen; Toy, Karen; Ha, Connie; Zhou, Wei; Song, Kyung; Friedman, Lori S; Amler, Lukas C; Hampton, Garret M; Moffat, John; Belvin, Marcia; Lackner, Mark R;

     View on PubMed

  • Potent and selective aminopyrimidine-based B-raf inhibitors with favorable physicochemical and pharmacokinetic properties

    Journal of Medicinal Chemistry, 2012, ISSN: 0022-2623

    Mathieu, Simon; Gradl, Stefan N; Ren, Li; Wen, Zhaoyang; Aliagas, Ignacio; Gunzner-Toste, Janet; Lee, Wendy; Pulk, Rebecca; Zhao, Guiling; Alicke, Bruno; Boggs, Jason W; Buckmelter, Alex J; Choo, Edna F; Dinkel, Victoria; Gloor, Susan L; Gould, Stephen E; Hansen, Joshua D; Hastings, Gregg; Hatzivassiliou, Georgia; Laird, Ellen R; Moreno, David; Ran, Yingqing; Voegtli, Walter C; Wenglowsky, Steve; Grina, Jonas; Rudolph, Joachim;

     View on PubMed

  • Live-cell microscopy reveals small molecule inhibitor effects on MAPK pathway dynamics

    PloS One, 2011 (epub: 04 Aug 2011), vol. 6, no. 8, p. e22607, ISSN: 1932-6203.

    Anderson, Daniel J; Durieux, Jenni K; Song, Kyung; Alvarado, Ryan; Jackson, Peter K; Hatzivassiliou, Georgia; Ludlam, Mary J C

     View on PubMed

  • RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

    Nature, 2010, ISSN: 1476-4687

    Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B.J.; Anderson, D.J.; Alvarado, R.; Ludlam, M.J.; Stokoe, D.; Gloor, S.L.; Vigers, G.; Morales, T.; Aliagas, I.; Liu, B.; Sideris, S.; Hoeflich, K.P.; Jaiswal, B.S.; Seshagiri, S.; Koeppen, H.; Belvin, M.; Friedman, L.S.; Malek, S.

• Education
  • Columbia University, Pathobiology, Ph.D. – 2001
  • Oberlin College, Biochemistry, B.A. – 1992